Table 3.
Neoadjuvant Trials with Immunotherapy in Triple-Negative Patients
| Neoadjuvant Regimens with Immunotherapy in Triple-Negative Breast Cancer | |||||
|---|---|---|---|---|---|
| Trial | Phase | # of Patients | Chemotherapy Regimen | Immune Checkpoint Inhibitor | pCR(%) with ICI Versus without |
| I-SPY2 | 2 | 250 | T → AC | Pembrolizumab | 60% vs 22% |
| KEYNOTE-522 | 3 | 602 | Cb + T → AC | Pembrolizumab | 65% vs 51% (p<0.001) |
| IMpassion031 | 3 | 333 | Nab-pac → AC | Atezolizumab | 58% vs 41% (p=0.004) |
| NeoTRIPaPDL1 | 3 | 280 | Cb + Nab-pac | Atezolizumab | 44% vs 41% (p=0.66) |
Abbreviations: A, anthracycline; Bev, bevacizumab; C, cyclophosphamide; Cb, carboplatin; Nab-pac, nabpaclitaxel; pCR, pathologic complete response; T, taxane; V, veliparib.